US · Healthcare · Medical Devices
EPS came in at -0.14 against a street estimate of -0.14 — a beat of 0.0%.
Analysts rate Pacific Biosciences of California a buy (4 buy, 3 hold, 1 sell out of 8) with an average price target of $2.40.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.40% |
| ARK Investment Management LLC | 9.58% |
| SoftBank Group Corp | 6.58% |
| Vanguard Capital Management, LLC | 4.31% |
| Geode Capital Management, LLC | 2.45% |
| Amova Asset Management Americas, Inc | 1.93% |
| Sumitomo Mitsui Trust Group Inc | 1.93% |
| State Street Corp | 1.92% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 HEADLINE NUMBERS • Q2 2026 revenue was $39.007 million, down from $39.766 million in Q2 2025. • Product revenue was $32.950 million versus $33.083 m | 2026-08-06 |
| Results announced · Q3 2026 HEADLINE NUMBERS • Q2 2026 revenue was $39.0 million, down from $39.8 million in Q2 2025. • GAAP net loss was $44.7 million, compared with $41.9 mil | 2026-08-05 |
| Board / officer change · Q3 2026 OTHER NOTABLE POINTS • Christopher M. Smith resigned from Pacific Biosciences’ board of directors effective immediately on July 8, 2026. • The compa | 2026-07-09 |
| Board / officer change · Q2 2026 HEADLINE NUMBERS • Pacific Biosciences held its annual shareholder meeting on June 3, 2026. • Of 310,487,099 shares outstanding as of the April 6, 2 | 2026-06-04 |
| Quarterly report · Q1 2026 HEADLINE NUMBERS • Q1 2026 revenue was $37.178 million, essentially flat versus $37.153 million in Q1 2025. • Product revenue increased to $31.534 m | 2026-05-08 |
| Results announced · Q2 2026 HEADLINE NUMBERS • Q1 2026 revenue was $37.2 million, essentially unchanged from $37.2 million in Q1 2025 and down from $44.645 million in Q4 2025. | 2026-05-07 |
| Proxy statement · Q2 2026 EXECUTIVE PAY • CEO Christian O. Henry’s total compensation for 2025 was not included in the provided excerpt, so the amount and year-over-year chang | 2026-04-23 |
| Annual report FY2025 HEADLINE NUMBERS • Fiscal year ended December 31, 2025; the filing does not provide complete fiscal 2025 revenue, margin, or loss figures in the supp | 2026-02-25 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pacific Biosciences of California — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.